CTLA-4
Posted: Tue Jun 08, 2021 7:18 am
2021 Jun 7
Clinical Neurosciences, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK/North Bristol NHS Trust, Bristol, UK
CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant
https://pubmed.ncbi.nlm.nih.gov/34097529/
Abstract
Background: The cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway acts as a negative immune regulator of T-cell activation and promotes self-tolerance.
Case: We report the first case of biopsy-proven central nervous system inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant.
Conclusion: This case has significant implications for the development of novel treatments for autoimmune conditions including multiple sclerosis and further emphasises the need for caution with clinical use of CTLA-4 immune checkpoint inhibitors in those with a history of inflammatory demyelination.
Clinical Neurosciences, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK/North Bristol NHS Trust, Bristol, UK
CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant
https://pubmed.ncbi.nlm.nih.gov/34097529/
Abstract
Background: The cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway acts as a negative immune regulator of T-cell activation and promotes self-tolerance.
Case: We report the first case of biopsy-proven central nervous system inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant.
Conclusion: This case has significant implications for the development of novel treatments for autoimmune conditions including multiple sclerosis and further emphasises the need for caution with clinical use of CTLA-4 immune checkpoint inhibitors in those with a history of inflammatory demyelination.